

# SAFETY & QUALITY OF MEDICINES GROUP

## Meeting

Thursday 25<sup>th</sup> August 2005

Time: 9.30am to 14.30pm

### Attendees

Dwayne Crombie - Chair  
 Beth Loe (Project Manager)  
 Gillian Bohm (MOH)  
 Avril Lee (Waitemata)  
 Mary Seddon (CMDHB)  
 Emil Schmitt (Otago)  
 Grant Howard (Waikato)  
 Marilyn Crawley (Waitemata)  
 Adam McRae (PHARMAC)  
 Dilky Rasiah (PHARMAC)  
 Tim Maling (CCDHB)

### Minutes

Item	Topic/agenda	Notes/comments	Action Required
1.	Apologies	Elizabeth Plant, Jane Vella Brincat, Peter Black, Peter Moodie	
2.	Minutes of meeting 30.6.05	<ul style="list-style-type: none"> <li>Agreed</li> </ul>	
3.	Membership of group	<ul style="list-style-type: none"> <li>Vicki Culling resigned</li> <li>Gershu Paul resigned</li> <li>GP member</li> </ul>	<ul style="list-style-type: none"> <li>Replace with consumer from PHARMAC consumer advisory group, PHARMAC to send list of group with CVs for SQM to decide (<b>Adam, Beth</b>)</li> <li>Peter to confirm with college (<b>Peter</b>)</li> </ul>
2.	Strategy	<ul style="list-style-type: none"> <li>Few minor changes to document suggested, reference to importance of having pharmaceuticals barcoded included</li> <li>Plan to launch strategy document at meeting 17<sup>th</sup> November in Wellington</li> <li>Invite Minister of Health</li> <li>Aim to publish early October</li> <li>Need media release via communications people from PHARMAC, MOH and DHB's</li> <li>Ensure strategy is circulated within MOH</li> <li>Liaison with media for release</li> <li>Group is responsible for driving strategy but other networks will be needed to participate to share workload</li> <li>Allocate different chapters to group members and identify the priorities for them to develop "action plan" with time frames for next 18mths</li> </ul>	<ul style="list-style-type: none"> <li>Make changes to document (<b>Beth</b>)</li> <li>Have strategy printed (<b>Beth</b>)</li> <li>Invitations to attend Nov meeting (<b>Beth</b>)</li> <li>Co-ordinate media release (<b>Beth</b>)</li> <li>Circulation in MOH (<b>Gillian</b>)</li> <li>Media liaison (<b>Dwayne, Tim, Peter</b>)</li> <li>Chapter allocations:           <ol style="list-style-type: none"> <li>Leadership and Coordination (<b>Dwayne</b>)</li> <li>DHB participation (<b>Avril, Gillian</b>)</li> <li>Best practice (<b>Marilyn, Tim, Emil</b>)</li> <li>High risk (<b>Peter Black, Emil</b>)</li> <li>Systems, processes etc (<b>Grant, Elizabeth</b> 1<sup>st</sup> 3 bullet points,</li> </ol> </li> </ul>

		<ul style="list-style-type: none"> <li>Chapter 5: Invite Minister to Wellington meeting in Nov to develop links, keying work into research projects that already have funding, PHO's key target area for 3<sup>rd</sup> bullet point but may be target DHB's first so they can drive it in both 1y and 2y care, needs to be on agenda in all organisations, 5<sup>th</sup> bullet point, need toolkits, QUM pharmacists at WDHB to evaluate Australian kit, if suitable use that and send out</li> <li>Chapter 9: review national drug chart and send it out as proposed national drug chart with idea being that individual DHB's can put their logo etc on, survey current infrastructure but look at original survey, Move discharge points to chapter 10, Australia about to release curriculum for safety and quality issues, look at curriculum at all schools providing education to health professionals, undergraduate and postgraduate, high priority to have common curriculum on safe and quality use of medicines, look at standard inclusion in orientation modules</li> <li>Chapter 10 highest priority EDS and including community pharmacy in discharge loop, look at admission medicines</li> <li>Chapter 11: bullet 3 &amp; 6 priority</li> <li>Chapter 12: consumer?</li> </ul>	<p><b>Mary, Tim</b> education) 10. Primary care/interface (<b>Emil, Adam, Avril</b>)</p> <ul style="list-style-type: none"> <li>Invite Minister (<b>Beth</b>)</li> <li>Evaluate Australian Quality Council toolkit (<b>WDHB QUM pharmacists</b>)</li> <li>Review national drug chart and send out from group (<b>Beth</b>)</li> <li>Move discharge bullets to chapter 10 (<b>Beth</b>)</li> <li>Provide template for action plans (<b>Beth</b>)</li> </ul>
	Bar Coding	<ul style="list-style-type: none"> <li>Invite interested parties to present different points of view on the issue of including bar coding on all pharmaceuticals – to happen at the November meeting in Wellington (same day as Strategy launch) Include GS1, Pharmacy Guild, TAG, MoH and DHB procurement representative, PHARMAC, HPAC member</li> </ul>	Representatives to be invited to present viewpoint / discussion ( <b>Beth</b> )
	Funding	<ul style="list-style-type: none"> <li>PreMec still has an active website and a sum of money</li> <li>PreMec AGM to decide what to do with money eg establish a trust and allow use to promote QUM projects</li> <li>Might be possible for the money to be available to either support small administration or support specific projects with project managers</li> <li>MOH would need to go to them with a project and ask for specific amount for that project, bids Jan/Feb</li> <li>Other sources DHB NZ &amp; ACC</li> <li>PHARMAC funding for 06/07 allocated but could bid for 07/08</li> </ul>	<ul style="list-style-type: none"> <li>Consider projects that could be basis for funding proposal (<b>All</b>)</li> </ul>
5.i	Potassium	<ul style="list-style-type: none"> <li>PHARMAC unable to consult about potassium until they are able to award national contracts</li> <li>HPAC meeting 25/8 and can give go</li> </ul>	<ul style="list-style-type: none"> <li>Letter to Medsafe asking that registration of a wider range of potassium pre-mixes be expedited (<b>Beth</b>)</li> </ul>

		<p>ahead to bulk fluid tendering process which means that consultation can go ahead</p> <ul style="list-style-type: none"> <li>• Commercial availability, already applied to Medsafe for registration of wider range of pre-mixes</li> <li>• Medsafe; need to register the concentrations chosen</li> <li>• DHB's need to review protocols/guidelines etc</li> </ul>	<ul style="list-style-type: none"> <li>• Update re-process in next newsletter <b>(Beth)</b></li> </ul>
5.ii	Warfarin	<ul style="list-style-type: none"> <li>• Video; process under way, possibly 3-6mths process</li> <li>• INR test strips; raised at GP conference and by individual GP <ul style="list-style-type: none"> <li>○ How accurate are they</li> <li>○ Currently no formal medical device evaluation in NZ</li> </ul> </li> <li>• Training pack for practice nurses; in development, liaising with CMDHB who have done work on accreditation</li> <li>• Nomogram and joint protocol for 3 Auckland region DHB's in final stages of development, send out pack in New Year to include possible nomogram, management guidance etc</li> <li>• Letter from PHARMAC: Cardiovascular subcommittee of PTAC have recommended not delisting either brand of warfarin</li> </ul>	<ul style="list-style-type: none"> <li>• Check international literature re reliability etc of strips <b>(Beth)</b></li> <li>• Check if TGA have assessed them <b>(Beth)</b></li> <li>• Training pack <b>(Avril)</b></li> <li>• Write to PHARMAC reiterating previous views as nothing in response to address issues raised in terms of risk. Give some numbers around people who are allergic and % market of the 2 brands <b>(Beth)</b></li> </ul>
5.iii	Heparin	<ul style="list-style-type: none"> <li>• Audit results available for all 3 Auckland DHB's, will be presented at pharmacy conference</li> <li>• Joint protocol and heparin prescribing chart will be forwarded now that warfarin is near completion</li> <li>• Alert re use of low molecular weight heparin in patients with reduced renal function ready for comment this week</li> <li>• Medsafe letter re value of anti Xa monitoring in this group of patients</li> </ul>	<ul style="list-style-type: none"> <li>• Work towards joint protocol and prescribing chart for heparin for Auckland region <b>(Beth)</b></li> <li>• Circulate alert for comments <b>(Beth)</b></li> <li>• Reply to Medsafe letter <b>(Grant, Peter)</b></li> </ul>
5.iv	Diltiazem	<ul style="list-style-type: none"> <li>• Cost of alert distribution to all community pharmacists, GP's, DHB's and wards: \$10000 ex GST for all non-laminated, \$12300 ex GST if laminated ID sheet</li> <li>• No funding available, send to identified contacts in DHB's and to PHO's. Investigate sending primary care version out via Primary Health Care Team</li> <li>• Letter from PHARMAC; no clinical need for both Dilzem SR 120mg and Cardizem CD 120mg and recommend delisting Dilzem SR 120mg but current contractual arrangements preclude this, immediate release preparations are subject to commercial arrangement until 30 June 2007</li> </ul>	<ul style="list-style-type: none"> <li>• Investigate Primary Health Care team <b>(Gillian)</b></li> <li>• Write to PHARMAC reiterating previous views as nothing in response to address issues raised in terms of risk. <b>(Beth)</b></li> <li>• Identify contacts in DHB's <b>(Beth)</b></li> </ul>
5.v	Insulin	<ul style="list-style-type: none"> <li>• Have identified that there are problems</li> </ul>	<ul style="list-style-type: none"> <li>• Contact diabetologists to ask</li> </ul>

		<ul style="list-style-type: none"> <li>Alert might not solve them</li> <li>Diabetologists unwilling to accept there is a problem</li> <li>Waikato diabetologists currently working on a programme</li> <li>CMDHB have funded project, could they include some work for group</li> </ul>	<ul style="list-style-type: none"> <li>for their help eg with sliding scale protocol</li> <li>Look at what is in RMO's handbook</li> </ul>
5.vi	Morphine	<ul style="list-style-type: none"> <li>Held to next meeting in absence of Jane and Emil (left meeting early)</li> </ul>	<ul style="list-style-type: none"> <li></li> </ul>
5.vii	Cytotoxics	<ul style="list-style-type: none"> <li>Proposal from NZHPA re – IT methotrexate, IV vincristine to be circulated to interested parties</li> <li>Compiling list of people to circulate to</li> </ul>	<ul style="list-style-type: none"> <li>Compile list and circulate <b>(Beth)</b></li> </ul>
5.viii	Intravenous infusions	<ul style="list-style-type: none"> <li>Synopsis of issues to be drawn up</li> </ul>	<ul style="list-style-type: none"> <li>Draw up synopsis of issues <b>(Marilyn, Emil)</b></li> </ul>
5.ix	Good prescribing practice	<ul style="list-style-type: none"> <li>Discussion about allowing some chemical names as abbreviations ie NaCl and KCl , should be not preferred rather than not allowed</li> <li>C&amp;CDHB raised issue of national drug chart and what was happening with it and consideration of what would happen when DHB's introduced electronic prescribing</li> </ul>	<ul style="list-style-type: none"> <li>Finalise alert <b>(Marilyn, Beth)</b></li> <li>Some changes to be made to chart, convert to document that can be branded by individual DHB's <b>(Beth)</b></li> <li>Consider putting use of the standard drug chart in the accreditation standards</li> <li>Review chart for electronic prescribing but need to standardise on one nationally first</li> </ul>
6.	Information Technology	<ul style="list-style-type: none"> <li>Need to re-audit which pharmacy systems DHBs are using/purchasing and where DHBs are going re electronic prescribing and systems to be employed</li> <li>GS1 NZ have completed an bar code audit of pharmaceuticals at a wholesalers. 21% of pharmaceuticals currently have bar code identification but very low percentage include batch code/expiry date information for traceability.</li> </ul>	<ul style="list-style-type: none"> <li>Look at audit of pharmacy and e prescribing systems <b>(Marilyn, Elizabeth, Emil)</b></li> <li>GS1 to issue media release about bar coding</li> </ul>
7.	Most effective method of information sharing	<ul style="list-style-type: none"> <li>Underway</li> </ul>	<ul style="list-style-type: none"> <li><b>(Beth)</b></li> </ul>
8.	Correspondence	<ul style="list-style-type: none"> <li>Feedback received from some DHB's re alert implementation</li> <li>Letter to deans of schools of medicine re lack of understanding PGY1's have around medicine prescribing from Waikato Medication Safety Committee requesting schools provide significant and robust training on all aspects of prescribing, administration &amp; funding</li> </ul>	
	Date of next meeting	<ul style="list-style-type: none"> <li>October 20<sup>th</sup> 2005 Auckland</li> </ul>	